Edwards Lifesciences (NYSE:EW) today unveiled its “Stay in the Race” initiative to support heart valve health.

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...

SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...

Edwards Lifesciences (NYSE:EW) reported first-quarter 2026 results that management said came in ahead of expectations, driven ...

Edwards Lifesciences today posted first-quarter financial results that came in ahead of the Wall Street forecast.

Edwards Lifesciences reported first-quarter earnings and revenue above Wall Street forecasts, driven by robust growth in heart valve therapies. The company raised its full-year 2026 sales and earnings ...

Edwards Lifesciences might be a pioneer in the transcatheter aortic valve replacement market, but that doesn’t mean it’s smooth sailing in the space. The Irvine, CA-based company faces stiff ...

Review staff from the US Food and Drug Administration (FDA) said Edwards Lifesciences' Sapien Transcatheter Heart Valve (THV) met trial endpoints for safety and effectiveness for the treatment of high ...

December 14, 2011 (Quebec City, Quebec City) — A small study has shed more light on atrial fibrillation (AF) following transcatheter aortic valve implantation (TAVI) demonstrating, perhaps most ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...